169 related articles for article (PubMed ID: 24598453)
1. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment.
Brayer J; Fishman M
J Immunother; 2014 Apr; 37(3):187-91. PubMed ID: 24598453
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
McDermott DF; Atkins MB
Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
McDermott DF; Regan MM; Atkins MB
Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
5. Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy.
Diner EK; Linehan M; Walther M
Int J Urol; 2005 Nov; 12(11):996-7. PubMed ID: 16351658
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab in the treatment of advanced renal cell carcinoma.
Arasaratnam M; Gurney H
Future Oncol; 2018 Jul; 14(17):1679-1689. PubMed ID: 29460635
[TBL] [Abstract][Full Text] [Related]
7. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
Pal SK; Hu A; Chang M; Figlin RA
Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
Joseph RW; Chatta G; Vaishampayan U
Urol Oncol; 2017 Apr; 35(4):142-148. PubMed ID: 28259541
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
[TBL] [Abstract][Full Text] [Related]
10. Aldesleukin in advanced renal cell carcinoma.
Schmidinger M; Hejna M; Zielinski CC
Expert Rev Anticancer Ther; 2004 Dec; 4(6):957-80. PubMed ID: 15606326
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.
Redman BG; Hillman GG; Flaherty L; Forman J; Dezso B; Haas GP
Clin Cancer Res; 1998 Feb; 4(2):283-6. PubMed ID: 9516912
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma.
Puchalski T; Prabhakar U; Jiao Q; Berns B; Davis HM
Clin Cancer Res; 2010 Mar; 16(5):1652-61. PubMed ID: 20179212
[TBL] [Abstract][Full Text] [Related]
13. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
Dutcher JP
Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
[No Abstract] [Full Text] [Related]
14. The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma.
Clement JM; McDermott DF
Clin Genitourin Cancer; 2009 Aug; 7(2):E7-9. PubMed ID: 19692326
[TBL] [Abstract][Full Text] [Related]
15. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Krajewski KM; Albiges L; Awad MM; Bellmunt J; Hodi FS; Choueiri TK
Cancer Immunol Res; 2016 Jan; 4(1):12-7. PubMed ID: 26589768
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics.
Bailey A; McDermott DF
Cancer J; 2013; 19(4):348-52. PubMed ID: 23867517
[TBL] [Abstract][Full Text] [Related]
18. Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence.
Adrianzen Herrera DA; Fleisig SB; Gartrell BA
Invest New Drugs; 2017 Oct; 35(5):665-668. PubMed ID: 28466375
[TBL] [Abstract][Full Text] [Related]
19. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
Hutson TE; Quinn DI
Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
[TBL] [Abstract][Full Text] [Related]
20. Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
McDermott DF
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
